Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)
Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)
Recruiting · NCT05686434 · Registry updated 2023-01-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2023-01-17 | NCT05686434 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Tianjin Medical University Cancer Institute and Hospital | 287 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Tianjin Medical University Cancer Institute & Hospital | Tianjin | China | 58 |